Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPHNE whole-body imaging in axial spondyloarthritis and psoriatic arthritis treated with ixekizumab
2024-510746-14-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ixekizumab in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in whole-body inflammatory burden by WB-MRI at 12 months. Planned start Apr 2024; status: authorised.
02
Drugs
ixekizumab
03
Conditions
axial spondyloarthritis (axSpA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2024-510746-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510746-14-00.